Overview

A Study of Deucravacitinib to Treat LPP and FFA

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Bristol-Myers Squibb
Treatments:
Deucravacitinib